Kunhi Ryu

Mr. Kunhi Ryu

Pharmacy, Yonsei University, Seoul, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2022 in The FASEB Journal
Verified
Journal Article
Open access
SJSungwoo Jo
Sungwoo Jo
RCRaquel Centeio
Raquel Centeio
JPJinhong Park
Jinhong Park
JOJiraporn Ousingsawat
Jiraporn Ousingsawat
DJDongkyu Jeon
Dongkyu Jeon
KKKarl Kunzelmann
Karl Kunzelmann
The solute carrier 26 family member A9 (SLC26A9) is an epithelial anion transporter that is assumed to contribute to airway chloride secretion and surface hydration. Whether SLC26A9 or CFTR is responsible for airway Cl − transport under basal conditions is still unclear, due to the lack of a specific inhibitor for SLC26A9. In the present study, we report a novel potent and specific inhibitor for SLC26A9, identified by screening of a drug‐like molecule library and subsequent chemical modifications. The most potent compound S9‐A13 inhibited SLC26A9 with an IC 50 of 90.9 ± 13.4 nM. S9‐A13 did not inhibit other members of the SLC26 family and had no effects on Cl − channels such as CFTR, TMEM16A, or VRAC. S9‐A13 inhibited SLC26A9 Cl − currents in cells that lack expression of CFTR. It also inhibited proton secretion by HGT‐1 human gastric cells. In contrast, S9‐A13 had minimal effects on ion transport in human airway epithelia and mouse trachea, despite clear expression of SLC26A9 in the apical membrane of ciliated cells. In both tissues, basal and stimulated Cl − secretion was due to CFTR, while acidification of airway surface liquid by S9‐A13 suggests a role of SLC26A9 for airway bicarbonate secretion.

Verified
Journal Article
Open access
PDF file
KRKunhi Ryu
Kunhi Ryu
Yunkyung HeoYunkyung Heo
Yunkyung Heo
LYLee yechan
Lee yechan
HJHyejin Jeon
Hyejin Jeon
WNWan Namkung
Wan Namkung
Chloroquine (CQ) is an antimalaria drug that has been widely used for decades. However, CQ-induced pruritus remains one of the major obstacles in CQ treatment for uncomplicated malaria. Recent studies have revealed that MrgprX1 plays an essential role in CQ-induced itch. To date, a few MrgprX1 antagonists have been discovered, but they are clinically unavailable or lack selectivity. Here, a cell-based high-throughput screening was performed to identify novel antagonists of MrgprX1, and the screening of 2543 compounds revealed two novel MrgprX1 inhibitors, berbamine and closantel. Notably, berbamine potently inhibited CQ-mediated MrgprX1 activation (IC50 = 1.6 μM) but did not alter the activity of other pruritogenic GPCRs. In addition, berbamine suppressed the CQ-mediated phosphorylation of ERK1/2. Interestingly, CQ-induced pruritus was significantly reduced by berbamine in a dose-dependent manner, but berbamine had no effect on histamine-induced, protease-activated receptors 2-activating peptide-induced, and deoxycholic acid-induced itch in mice. These results suggest that berbamine is a novel, potent, and selective antagonist of MrgprX1 and may be a potential drug candidate for the development of therapeutic agents to treat CQ-induced pruritus.